Peptide Bioavailability: Why Your Expensive Peptides Might Be Going to Waste

You just spent $200 on a peptide that your body might be destroying before it ever reaches its target. Bioavailability — the percentage that actually makes it into your bloodstream in active form — is the most important variable in peptide therapy that almost nobody talks about. If you’re not optimizing delivery, you’re burning money.

I’m Tony Huge, and the difference between a peptide that works and one that disappoints often has nothing to do with the compound itself — it’s entirely about delivery. This guide will change how you approach every peptide in your Enhanced Athlete Protocol peptide stack.

Why Peptide Bioavailability Matters

Peptide bonds that give peptides their activity also make them vulnerable to enzymatic degradation by proteases in gut, blood, and tissues. Oral bioavailability of most unmodified peptides is below 2%. A 5mg capsule delivers less than 0.1mg to your bloodstream. Delivery method is everything.

Delivery Methods Ranked by Bioavailability

1. Intravenous (IV) — 100%

Direct bloodstream injection bypasses all barriers. Used for NAD+ IV therapy. Requires medical supervision. Gold standard but impractical for daily self-administration.

2. Subcutaneous Injection — 65-95%

Standard for most peptide therapy. Insulin syringe (29-31 gauge) into subcutaneous fat. This is how BPC-157/TB-500, CJC-1295 + Ipamorelin, and most research peptides are administered. Optimize by: rotating injection sites, injecting slowly, ensuring full dissolution, maintaining sterile technique.

3. Intranasal — 10-50%

Richly vascularized nasal mucosa partially bypasses first-pass metabolism. Olfactory nerve provides direct nose-to-brain pathway. Selank and Semax were designed for this route. Tips: tilt head forward, aim toward outer nostril wall, sniff gently, avoid blowing nose for 15 minutes.

4. Sublingual/Buccal — 5-25%

Oral mucosa absorption, partially bypassing digestion. Works best for small peptides (under 10 amino acids) with moderate lipophilicity. BPC-157 has some sublingual efficacy, though less than injection.

5. Oral — 1-5% (with exceptions)

Worst for most peptides. Engineering approaches help: enteric coating, permeation enhancers (SNAC), cyclic structures. BPC-157 is somewhat unique with partial oral activity. MK-677 is orally active with good bioavailability as an exception.

6. Transdermal — 1-20%

Generally poor due to stratum corneum barrier. Advances in microneedle patches and penetration enhancers are improving this. GHK-Cu is commonly used topically for skin-specific effects where systemic bioavailability matters less.

Peptide-Specific Optimization

Growth Hormone Secretagogues

CJC-1295/Ipamorelin, Hexarelin, GHRP-2/6: must be taken fasted (minimum 2 hours). Blood sugar and insulin blunt GH release. Administer before bed or first morning for maximum GH pulse.

Healing Peptides

BPC-157/TB-500: subcutaneous near injury for systemic healing; oral BPC-157 for gut healing delivers direct mucosal exposure. TB-500 has ~2 week half-life, allowing less frequent dosing.

Nootropic Peptides

Selank/Semax, Dihexa: intranasal preferred for direct CNS access via olfactory pathway, bypassing blood-brain barrier.

The Reconstitution Factor

Bioavailability starts at reconstitution. Wrong diluent, aggressive injection into lyophilized powder, or improper storage can denature peptides before you inject them. See the reconstitution guide and storage stability guide.

Timing and Food Interactions

Fasting peptides: All GH secretagogues, peptides where peak plasma concentration matters. 2+ hours after eating, 30 minutes before next meal.

Don’t combine multiple GH secretagogues simultaneously — they compete for receptor activation. Space by 3+ hours. See peptide cycling strategies.

Interesting Perspectives

While the core principles of peptide delivery are well-established, several emerging and unconventional perspectives challenge the standard models. Some researchers are exploring the concept of “local bioavailability” over systemic, arguing that for peptides like BPC-157, direct tissue exposure via oral administration for gut issues or localized injection for tendons may be more critical than high serum levels. This aligns with the Tony Huge Laws of Biochemistry Physics, where the site of action dictates the optimal route, not just the highest absorption percentage.

Another contrarian view questions the obsession with absolute bioavailability percentages. For certain nootropic peptides targeting the CNS, the intranasal route’s ability to utilize the olfactory and trigeminal nerve pathways for direct brain delivery might offer a superior therapeutic index than a higher systemic bioavailability from subcutaneous injection that then has to cross the blood-brain barrier. The pharmacokinetic profile—how the concentration changes over time at the target site—can be more important than the total amount absorbed.

Finally, the field of peptide engineering is creating new exceptions. The development of stapled peptides, cell-penetrating peptides (CPPs), and fusion technologies with albumin-binding domains or Fc regions are fundamentally rewriting the rules of bioavailability, creating orally active versions of previously injection-only molecules. The future may see bioavailability become a programmable feature of the peptide itself, rather than a limitation of its administration.

The Bottom Line

The most expensive peptide is worthless if it never reaches its target receptor. Bioavailability optimization is the difference between results and wasted money. Choose the right delivery method, follow preparation best practices, and time doses for maximum absorption. Visit the peptides tier for the complete framework.

It’s not just what you take — it’s how much actually gets where it needs to go.